Papel de los biomarcadores en el cáncer urotelial

Previous Page

Next Page

Page Background

Rosenberg, JE et al. Lancet 2016

N=310

Phase II, 2L atezolizumab after progression to platins

predicts outcome in metastatic

urothelial cancer treated with

atezolizumab